Antifungal stewardship considerations for adults and pediatrics

References

• Ananda-Rajah MR, Slavin MA, Thursky KT. The case for antifungal stewardship. Curr Opin Infect Dis 2012; 25:107-15; PMID:22123667; http://dx.doi.org/10.1097/QCO.0b013e32834e0680
   PubMed Web of Science ®Google Scholar
• Barlam TF, Cosgrove SE, Abbo LM, MacDougall C, Schuetz AN, Septimus EJ, Srinivasan A, Dellit TH, Falck-Ytter YT, Fishman NO, et al. Implementing an antibiotic stewardship program: guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Clin Infect Dis 2016; 62:e51-77; PMID:27080992; http://dx.doi.org/10.1093/cid/ciw118
   PubMed Web of Science ®Google Scholar
• Dellit TH, Owens RC, McGowan JE, Jr, Gerding DN, Weinstein RA, Burke JP, Huskins WC, Paterson DL, Fishman NO, Carpenter CF, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007; 44:159-77; PMID:17173212; http://dx.doi.org/10.1086/510393
   PubMed Web of Science ®Google Scholar
• Mihu C, Paskovaty A, Seo SK. Antimicrobial stewardship considerations for cancer centers. In Safdar A, ed. Principles and Practice of Cancer Infectious Diseases. 1st ed. Totowa, NJ: Humana Press;2011:491-498
   Google Scholar
• Tverdek FP, Rolston KV, Chemaly RF. Antimicrobial stewardship in patients with cancer. Pharmacotherapy 2012; 32:722-34; PMID:23307520; http://dx.doi.org/10.1002/j.1875-9114.2012.01162.x
   PubMed Web of Science ®Google Scholar
• Abbo LM, Ariza-Heredia EJ. Antimicrobial stewardship in immunocompromised hosts. Infect Dis Clin North Am 2014; 28:263-79; PMID:24857392; http://dx.doi.org/10.1016/j.idc.2014.01.008
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Pappas PG, Wingard JR. Invasive fungal pathogens: current epidemiological trends. Clin Infect Dis 2006; 43:S3-S14; http://dx.doi.org/10.1086/504490
   Web of Science ®Google Scholar
• Pagano L, Caira M, Candoni A, Offidani M, Fianchi L, Martino B, Pastore D, Picardi M, Bonini A, Chierichini A, et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica 2006; 91:1068-75; PMID:16885047
   PubMed Web of Science ®Google Scholar
• Kontoyiannis DP, Marr KA, Park BJ, Alexander BD, Anaissie EJ, Walsh TJ, Ito J, Andes DR, Baddley JW, Brown JM, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001–2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis 2010; 50:1091-100; PMID:20218877; http://dx.doi.org/10.1086/651263
   PubMed Web of Science ®Google Scholar
• van Burik JH, Leisenring W, Myerson D, Hackman RC, Shulman HM, Sale GE, Bowden RA, McDonald GB. The effect of prophylactic fluconazole on the clinical spectrum of fungal diseases in bone marrow transplant recipients with special attention to hepatic candidiasis. An autopsy study of 355 patients. Medicine (Baltimore) 1998; 77:246-54; PMID:9715729; http://dx.doi.org/10.1097/00005792-199807000-00003
   PubMed Web of Science ®Google Scholar
• Pappas PG, Alexander BD, Andes DR, Hadley S, Kauffman CA, Freifeld A, Anaissie EJ, Brumble LM, Herwaldt L, Ito J, et al. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis 2010; 50:1101-11; PMID:20218876; http://dx.doi.org/10.1086/651262
   PubMed Web of Science ®Google Scholar
• Ananda-Rajah MR, Cheng A, Morrissey CO, Spelman T, Dooley M, Neville AM, Slavin M. Attributable hospital cost and antifungal treatment of invasive fungal diseases in high-risk hematology patients: an economic modeling approach. Antimicrob Agents Chemother 2011; 55:1953-60; PMID:21357302; http://dx.doi.org/10.1128/AAC.01423-10
   PubMed Web of Science ®Google Scholar
• Morgan J, Meltzer MI, Plikaytis BD, Sofair AN, Huie-White S, Wilcox S, Harrison LH, Seaberg EC, Hajjeh RA, Teutsch SM. Excess mortality, hospital stay, and cost due to candidemia: a case-control study using data from population-based candidemia surveillance. Infect Control Hosp Epidemiol 2005; 26:540-7; PMID:16018429; http://dx.doi.org/10.1086/502581
   PubMed Web of Science ®Google Scholar
• Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005; 49:3640-5; PMID:16127033; http://dx.doi.org/10.1128/AAC.49.9.3640-3645.2005
   PubMed Web of Science ®Google Scholar
• Garey KW, Rege M, Pai MP, Mingo DE, Suda KJ, Turpin RS, Bearden DT. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 2006; 43:25-31; PMID:16758414; http://dx.doi.org/10.1086/504810
   PubMed Web of Science ®Google Scholar
• Aisner J, Wiernik PH, Schimpff SC. Treatment of invasive aspergillosis: relation of early diagnosis and treatment to response. Ann Intern Med 1977; 86:539-43; PMID:851301; http://dx.doi.org/10.7326/0003-4819-86-5-539
   PubMed Web of Science ®Google Scholar
• Chamilos G, Lewis RE, Kontoyiannis DP. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis 2008; 47:503-9; PMID:18611163; http://dx.doi.org/10.1086/590004
   PubMed Web of Science ®Google Scholar
• Li MC, Lee NY, Lee CC, Lee HC, Chang CM, Ko WC. Pneumocystis jiroveci pneumonia in immunocompromised patients: delayed diagnosis and poor outcomes in non-HIV-infected individuals. J Microbiol Immunol Infect 2014; 47:42-7; PMID:23063081; http://dx.doi.org/10.1016/j.jmii.2012.08.024
   PubMedGoogle Scholar
• Arvanitis M, Anagnostou T, Fuchs BB, Caliendo AM, Mylonakis E. Molecular and nonmolecular diagnostic methods for invasive fungal infections. Clin Microbiol Rev 2014; 27:490-526; PMID:24982319; http://dx.doi.org/10.1128/CMR.00091-13
   PubMed Web of Science ®Google Scholar
• Gross BN, Steib-Bauert M, Kern WV, Knoth H, Borde JP, Krebs S, Hug MJ, Rothe U, Maier L, de With K. Hospital use of systemic antifungal drugs: a multi-center surveillance update from Germany. Infection 2015; 43:423-9; PMID:25687588; http://dx.doi.org/10.1007/s15010-015-0742-5
   PubMed Web of Science ®Google Scholar
• Meyer E, Schwab F, Gastmeier P, Ruden H, Heininger A. Antifungal use in intensive care units. J Antimicrob Chemother 2007; 60:619-24; PMID:17609195; http://dx.doi.org/10.1093/jac/dkm255
   PubMed Web of Science ®Google Scholar
• Salci TP, Gimenes M, dos Santos CA, Svidzinski TI, Caparroz-Assef SM. Utilization of fluconazole in an intensive care unit at a university hospital in Brazil. Int J Clin Pharm 2013; 35:176-80; PMID:23187962; http://dx.doi.org/10.1007/s11096-012-9726-z
   PubMed Web of Science ®Google Scholar
• Olaechea-Astigarraga PM, Alvarez-Lerma F, Palomar-Martinez M, Insausti-Ordenana J, Lopez-Pueyo MJ, Seijas-Betolaza I, Otal-Entraigas JJ, Gimeno-Costa R, Gracia-Arnillas MP; Grupo ENVIN-HELICS. [Trends in systemic antifungal use in critically ill patients. Multicenter observational study, 2006–2010]. Enferm Infecc Microbiol Clin 2012; 30:435-40; PMID:22463989; http://dx.doi.org/10.1016/j.eimc.2012.02.006
   PubMed Web of Science ®Google Scholar
• Guillot J, Lebel D, Roy H, Ovetchkine P, Bussieres JF. Usefulness of defined daily dose and days of therapy in pediatrics and obstetrics-gynecology: a comparative analysis of antifungal drugs (2000–2001, 2005–2006, and 2010–2011). J Pediatr Pharmacol Ther 2014; 19:196-201; PMID:25309150; http://dx.doi.org/10.5863/1551-6776-19.3.196
   PubMedGoogle Scholar
• Lehrnbecher T, Ethier MC, Zaoutis T, Creutzig U, Gamis A, Reinhardt D, Aplenc R, Sung L. International variations in infection supportive care practices for paediatric patients with acute myeloid leukaemia. Br J Haematol 2009; 147:125-8; PMID:19663826; http://dx.doi.org/10.1111/j.1365-2141.2009.07844.x
   PubMed Web of Science ®Google Scholar
• Santolaya ME, Alvarado T, Queiroz-Telles F, Colombo AL, Zurita J, Tiraboschi IN, Cortes JA, Thompson L, Guzman M, Sifuentes J, et al. Active surveillance of candidemia in children from Latin America: a key requirement for improving disease outcome. Pediatr Infect Dis J 2014; 33:e40-4; PMID:23995591; http://dx.doi.org/10.1097/INF.0000000000000039
   PubMed Web of Science ®Google Scholar
• Kavcic M, Fisher BT, Gerber JS, Leckerman KH, Li YM, Huang YS, Seif AE, Torp K, Bagatell R, Aplenc R. Variability in antifungal use for pediatric acute myeloid leukemia at children's hospitals across the United States. Blood 2012; 120:abstract 4278; PMID:23175659; http://dx.doi.org/10.1182/blood-2012-09-451476
   PubMed Web of Science ®Google Scholar
• Lestner JM, Versporten A, Doerholt K, Warris A, Roilides E, Sharland M, Bielicki J, Goossens H; ARPEC Project Group. Systemic antifungal prescribing in neonates and children: outcomes from the Antibiotic Resistance and Prescribing in European Children (ARPEC) Study. Antimicrob Agents Chemother 2015; 59:782-9; PMID:25403672; http://dx.doi.org/10.1128/AAC.04109-14
   PubMed Web of Science ®Google Scholar
• Menson EN, Walker AS, Sharland M, Wells C, Tudor-Williams G, Riordan FA, Lyall EG, Gibb DM; Collaborative HIV Paediatric Study Steering Committee. Underdosing of antiretrovirals in UK and Irish children with HIV as an example of problems in prescribing medicines to children, 1997–2005: cohort study. BMJ 2006; 332:1183-7; PMID:16709991; http://dx.doi.org/10.1136/bmj.332.7551.1183
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013. Atlanta, GA: United States Department of Health and Human Services; 2013 Apr 23 [accessed 2016 Apr 15]. http://www.cdc.gov/drugresistance/pdf/ar-threats-2013-508.pdf.
   Google Scholar
• Cleveland AA, Harrison LH, Farley MM, Hollick R, Stein B, Chiller TM, Lockhart SR, Park BJ. Declining incidence of candidemia and the shifting epidemiology of Candida resistance in two US metropolitan areas, 2008–2013: results from population-based surveillance. PLoS One 2015; 10:e0120452; PMID:25822249; http://dx.doi.org/10.1371/journal.pone.0120452
   PubMed Web of Science ®Google Scholar
• Farmakiotis D, Tarrand JJ, Kontoyiannis DP. Drug-resistant Candida glabrata infection in cancer patients. Emerg Infect Dis 2014; 20:1833-40; PMID:25340258; http://dx.doi.org/10.3201/eid2011.140685
   PubMed Web of Science ®Google Scholar
• Jung DS, Farmakiotis D, Jiang Y, Tarrand JJ, Kontoyiannis DP. Uncommon Candida species fungemia among cancer patients, Houston, Texas, USA. Emerg Infect Dis 2015; 21:1942-50; PMID:26488845; http://dx.doi.org/10.3201/eid2111.150404
   PubMed Web of Science ®Google Scholar
• Xu R, Polk RE, Stencel L, Lowe DK, Guharoy R, Duggal RW, Wiest M, Putney KS, Flint NB. Antibiogram compliance in University HealthSystem Consortium participating hospitals with Clinical and Laboratory Standards Institute guidelines. Am J Health Syst Pharm 2012; 69:598-606; PMID:22441793; http://dx.doi.org/10.2146/ajhp110332
   PubMed Web of Science ®Google Scholar
• Moehring RW, Hazen KC, Hawkins MR, Drew RH, Sexton DJ, Anderson DJ. Challenges in preparation of cumulative antibiogram reports for community hospitals. J Clin Microbiol 2015; 53:2977-82; PMID:26179303; http://dx.doi.org/10.1128/JCM.01077-15
   PubMed Web of Science ®Google Scholar
• Lortholary O, Desnos-Ollivier M, Sitbon K, Fontanet A, Bretagne S, Dromer F; French Mycosis Study Group. Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2,441 patients. Antimicrob Agents Chemother 2011; 55:532-8; PMID:21078946; http://dx.doi.org/10.1128/AAC.01128-10
   PubMed Web of Science ®Google Scholar
• Kim SH, Shin JH, Kim EC, Lee K, Kim MN, Lee WG, Uh Y, Lee HS, Lee MK, Jeong SH, et al. The relationship between antifungal usage and antifungal susceptibility in clinical isolates of Candida: a multicenter Korean study. Med Mycol 2009; 47:296-304; PMID:18668423; http://dx.doi.org/10.1080/13693780802291445
   PubMed Web of Science ®Google Scholar
• Fournier P, Schwebel C, Maubon D, Vesin A, Lebeau B, Foroni L, Hamidfar-Roy R, Cornet M, Timsit JF, Pelloux H. Antifungal use influences Candida species distribution and susceptibility in the intensive care unit. J Antimicrob Chemother 2011; 66:2880-6; PMID:21980066; http://dx.doi.org/10.1093/jac/dkr394
   PubMed Web of Science ®Google Scholar
• Shah DN, Yau R, Lasco TM, Weston J, Salazar M, Palmer HR, Garey KW. Impact of prior inappropriate fluconazole dosing on isolation of fluconazole-nonsusceptible Candida species in hospitalized patients with candidemia. Antimicrob Agents Chemother 2012; 56:3239-43; PMID:22411611; http://dx.doi.org/10.1128/AAC.00019-12
   PubMed Web of Science ®Google Scholar
• van der Linden JW, Arendrup MC, Warris A, Lagrou K, Pelloux H, Hauser PM, Chryssanthou E, Mellado E, Kidd SE, Tortorano AM, et al. Prospective multicenter international surveillance of azole resistance in Aspergillus fumigatus. Emerg Infect Dis 2015; 21:1041-4; PMID:25988348; http://dx.doi.org/10.3201/eid2106.140717
   PubMed Web of Science ®Google Scholar
• Faria-Ramos I, Farinha S, Neves-Maia J, Tavares PR, Miranda IM, Estevinho LM, Pina-Vaz C, Rodrigues AG. Development of cross-resistance by Aspergillus fumigatus to clinical azoles following exposure to prochloraz, an agricultural azole. BMC Microbiol 2014; 14:155; PMID:24920078; http://dx.doi.org/10.1186/1471-2180-14-155
   PubMed Web of Science ®Google Scholar
• European Centre for Disease Prevention and Control. Risk assessment on the impact of environmental usage of triazoles on the development and spread of resistance to medical triazoles in Aspergillus species. Stockholm: ECDC; 2013 February [accessed 2016 Apr 16]. http://ecdc.europa.eu/en/publications/publications/risk-assessment-impact-environmental-usage-of-triazoles-on-aspergillus-spp-resistance-to-medical-triazoles.pdf.
   Google Scholar
• van der Linden JW, Snelders E, Kampinga GA, Rijnders BJ, Mattsson E, Debets-Ossenkopp YJ, Kuijper EJ, Van Tiel FH, Melchers WJ, Verweij PE. Clinical implications of azole resistance in Aspergillus fumigatus, The Netherlands, 2007–2009. Emerg Infect Dis 2011; 17:1846-54; PMID:22000354; http://dx.doi.org/10.3201/eid1710.110226
   PubMed Web of Science ®Google Scholar
• van der Linden JW, Arendrup MC, Melchers WJ, Verweij PE. Azole resistance of Aspergillus fumigatus in immunocompromised patients with invasive aspergillosis. Emerg Infect Dis 2016; 22:158-9; PMID:26691166; http://dx.doi.org/10.3201/eid2201.151308
   PubMed Web of Science ®Google Scholar
• Fournel I, Sautour M, Lafon I, Sixt N, L'Ollivier C, Dalle F, Chavanet P, Couillaud G, Caillot D, Astruc K, et al. Airborne Aspergillus contamination during hospital construction works: efficacy of protective measures. Am J Infect Control 2010; 38:189-94; PMID:19923037; http://dx.doi.org/10.1016/j.ajic.2009.07.011
   PubMed Web of Science ®Google Scholar
• Millon L, Herbrecht R, Grenouillet F, Morio F, Alanio A, Letscher-Bru V, Cassaing S, Chouaki T, Kauffmann-Lacroix C, Poirier P, et al. Early diagnosis and monitoring of mucormycosis by detection of circulating DNA in serum: retrospective analysis of 44 cases collected through the French Surveillance Network of Invasive Fungal Infections (RESSIF). Clin Microbiol Infect 2015. pii: S1198-743X(15)01032-0; PMID:26706615; http://dx.doi.org/10.1016/j.cmi.2015.12.006
   PubMed Web of Science ®Google Scholar
• Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39:309-17; PMID:15306996; http://dx.doi.org/10.1086/421946
   PubMed Web of Science ®Google Scholar
• Clancy CJ, Nguyen MH. Finding the “missing 50%” of invasive candidiasis: how nonculture diagnostics will improve understanding of disease spectrum and transform patient care. Clin Infect Dis 2013; 56:1284-92; PMID:23315320; http://dx.doi.org/10.1093/cid/cit006
   PubMed Web of Science ®Google Scholar
• Bauer KA, Perez KK, Forrest GN, Goff DA. Review of rapid diagnostic tests used by antimicrobial stewardship programs. Clin Infect Dis 2014; 59(Suppl 3):S134-45; PMID:25261540; http://dx.doi.org/10.1093/cid/ciu547
   PubMed Web of Science ®Google Scholar
• Huang AM, Newton D, Kunapuli A, Gandhi TN, Washer LL, Isip J, Collins CD, Nagel JL. Impact of rapid organism identification via matrix-assisted laser desorption/ionization time-of-flight combined with antimicrobial stewardship team intervention in adult patients with bacteremia and candidemia. Clin Infect Dis 2013; 57:1237-45; PMID:23899684; http://dx.doi.org/10.1093/cid/cit498
   PubMed Web of Science ®Google Scholar
• Banerjee R, Teng CB, Cunningham SA, Ihde SM, Steckelberg JM, Moriarty JP, Shah ND, Mandrekar JN, Patel R. Randomized trial of rapid multiplex polymerase chain reaction-based blood culture identification and susceptibility testing. Clin Infect Dis 2015; 61:1071-80; PMID:26197846; http://dx.doi.org/10.1093/cid/civ447
   PubMed Web of Science ®Google Scholar
• Forrest GN, Mankes K, Jabra-Rizk MA, Weekes E, Johnson JK, Lincalis DP, Venezia RA. Peptide nucleic acid fluorescence in situ hybridization-based identification of Candida albicans and its impact on mortality and antifungal therapy costs. J Clin Microbiol 2006; 44:3381-3; PMID:16954279; http://dx.doi.org/10.1128/JCM.00751-06
   PubMed Web of Science ®Google Scholar
• Heil EL, Daniels LM, Long DM, Rodino KG, Weber DJ, Miller MB. Impact of a rapid peptide nucleic acid fluorescence in situ hybridization assay on treatment of Candida infections. Am J Health Syst Pharm 2012; 69:1910-4; PMID:23111676; http://dx.doi.org/10.2146/ajhp110604
   PubMed Web of Science ®Google Scholar
• Nguyen MH, Wissel MC, Shields RK, Salomoni MA, Hao B, Press EG, Shields RM, Cheng S, Mitsani D, Vadnerkar A, et al. Performance of Candida real-time polymerase chain reaction, β-D-glucan assay, and blood cultures in the diagnosis of invasive candidiasis. Clin Infect Dis 2012; 54:1240-8; PMID:22431804; http://dx.doi.org/10.1093/cid/cis200
   PubMed Web of Science ®Google Scholar
• Mylonakis E, Clancy CJ, Ostrosky-Zeichner L, Garey KW, Alangaden GJ, Vazquez JA, Groeger JS, Judson MA, Vinagre YM, Heard SO, et al. T2 magnetic resonance assay for the rapid diagnosis of candidemia in whole blood: a clinical trial. Clin Infect Dis 2015; 60:892-9; PMID:25586686; http://dx.doi.org/10.1093/cid/ciu959
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Wolk DM, Lowery TJ. T2MR and T2Candida: novel technology for the rapid diagnosis of candidemia and invasive candidiasis. Future Microbiol 2016; 11:103-17; PMID:26371384; http://dx.doi.org/10.2217/fmb.15.111
   PubMed Web of Science ®Google Scholar
• Holtzman C, Whitney D, Barlam T, Miller NS. Assessment of impact of peptide nucleic acid fluorescence in situ hybridization for rapid identification of coagulase-negative staphylococci in the absence of antimicrobial stewardship intervention. J Clin Microbiol 2011; 49:1581-2; PMID:21270213; http://dx.doi.org/10.1128/JCM.02461-10
   PubMed Web of Science ®Google Scholar
• Cadena J, Thompson GR, 3rd, Patterson TF. Invasive aspergillosis: current strategies for diagnosis and management. Infect Dis Clin North Am 2016; 30:125-42; PMID:26897064; http://dx.doi.org/10.1016/j.idc.2015.10.015
   PubMed Web of Science ®Google Scholar
• de Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, Pappas PG, Maertens J, Lortholary O, Kauffman CA, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46:1813-21; PMID:18462102; http://dx.doi.org/10.1086/588660
   PubMed Web of Science ®Google Scholar
• Miceli MH, Maertens J. Role of non-culture-based tests, with an emphasis on galactomannan testing for the diagnosis of invasive aspergillosis. Semin Respir Crit Care Med 2015; 36:650-61; PMID:26398532; http://dx.doi.org/10.1055/s-0035-1562892
   PubMed Web of Science ®Google Scholar
• Arvanitis M, Ziakas PD, Zacharioudakis IM, Zervou FN, Caliendo AM, Mylonakis E. PCR in diagnosis of invasive aspergillosis: a meta-analysis of diagnostic performance. J Clin Microbiol 2014; 52:3731-42; PMID:25122854; http://dx.doi.org/10.1128/JCM.01365-14
   PubMed Web of Science ®Google Scholar
• Lamoth F, Alexander BD. Nonmolecular methods for the diagnosis of respiratory fungal infections. Clin Lab Med 2014; 34:315-36; PMID:24856530; http://dx.doi.org/10.1016/j.cll.2014.02.006
   PubMed Web of Science ®Google Scholar
• Pfeiffer CD, Fine JP, Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis 2006; 42:1417-27; PMID:16619154; http://dx.doi.org/10.1086/503427
   PubMed Web of Science ®Google Scholar
• Leeflang MM, Debets-Ossenkopp YJ, Visser CE, Scholten RJ, Hooft L, Bijlmer HA, Reitsma JB, Bossuyt PM, Vandenbroucke-Grauls CM. Galactomannan detection for invasive aspergillosis in immunocompromized patients. Cochrane Database Syst Rev 2008; CD007394; PMID:18843747; http://dx.doi.org/10.1002/14651858.CD007394
   PubMed Web of Science ®Google Scholar
• Karageorgopoulos DE, Vouloumanou EK, Ntziora F, Michalopoulos A, Rafailidis PI, Falagas ME. β-D-glucan assay for the diagnosis of invasive fungal infections: a meta-analysis. Clin Infect Dis 2011; 52:750-70; PMID:21367728; http://dx.doi.org/10.1093/cid/ciq206
   PubMed Web of Science ®Google Scholar
• Lu Y, Chen YQ, Guo YL, Qin SM, Wu C, Wang K. Diagnosis of invasive fungal disease using serum (1–>3)-β-D-glucan: a bivariate meta-analysis. Intern Med 2011; 50:2783-91; PMID:22082890; http://dx.doi.org/10.2169/internalmedicine.50.6175
   PubMed Web of Science ®Google Scholar
• Lamoth F, Cruciani M, Mengoli C, Castagnola E, Lortholary O, Richardson M, Marchetti O; Third European Conference on Infections in Leukemia (ECIL-3). β-glucan antigenemia assay for the diagnosis of invasive fungal infections in patients with hematological malignancies: a systematic review and meta-analysis of cohort studies from the Third European Conference on Infections in Leukemia (ECIL-3). Clin Infect Dis 2012; 54:633-43; PMID:22198786; http://dx.doi.org/10.1093/cid/cir897
   PubMed Web of Science ®Google Scholar
• Onishi A, Sugiyama D, Kogata Y, Saegusa J, Sugimoto T, Kawano S, Morinobu A, Nishimura K, Kumagai S. Diagnostic accuracy of serum 1,3-β-D-glucan for pneumocystis jiroveci pneumonia, invasive candidiasis, and invasive aspergillosis: systematic review and meta-analysis. J Clin Microbiol 2012; 50:7-15; PMID:22075593; http://dx.doi.org/10.1128/JCM.05267-11
   PubMed Web of Science ®Google Scholar
• Lamoth F. Galactomannan and 1,3-B-D-glucan testing for the diagnosis of invasive aspergillosis. J Fungi 2016; 2:1-8; http://dx.doi.org/10.3390/jof2030022
   Google Scholar
• Pazos C, Ponton J, Del Palacio A. Contribution of (1->3)-β-D-glucan chromogenic assay to diagnosis and therapeutic monitoring of invasive aspergillosis in neutropenic adult patients: a comparison with serial screening for circulating galactomannan. J Clin Microbiol 2005; 43:299-305; PMID:15634986; http://dx.doi.org/10.1128/JCM.43.1.299-305.2005
   PubMed Web of Science ®Google Scholar
• Guo YL, Chen YQ, Wang K, Qin SM, Wu C, Kong JL. Accuracy of BAL galactomannan in diagnosing invasive aspergillosis: a bivariate metaanalysis and systematic review. Chest 2010; 138:817-24; PMID:20453070; http://dx.doi.org/10.1378/chest.10-0488
   PubMed Web of Science ®Google Scholar
• Zou M, Tang L, Zhao S, Zhao Z, Chen L, Chen P, Huang Z, Li J, Chen L, Fan X. Systematic review and meta-analysis of detecting galactomannan in bronchoalveolar lavage fluid for diagnosing invasive aspergillosis. PLoS One 2012; 7:e43347; PMID:22905261; http://dx.doi.org/10.1371/journal.pone.0043347
   PubMed Web of Science ®Google Scholar
• Clancy CJ, Jaber RA, Leather HL, Wingard JR, Staley B, Wheat LJ, Cline CL, Rand KH, Schain D, Baz M, et al. Bronchoalveolar lavage galactomannan in diagnosis of invasive pulmonary aspergillosis among solid-organ transplant recipients. J Clin Microbiol 2007; 45:1759-65; PMID:17428933; http://dx.doi.org/10.1128/JCM.00077-07
   PubMed Web of Science ®Google Scholar
• Luong ML, Clancy CJ, Vadnerkar A, Kwak EJ, Silveira FP, Wissel MC, Grantham KJ, Shields RK, Crespo M, Pilewski J, et al. Comparison of an Aspergillus real-time polymerase chain reaction assay with galactomannan testing of bronchoalvelolar lavage fluid for the diagnosis of invasive pulmonary aspergillosis in lung transplant recipients. Clin Infect Dis 2011; 52:1218-26; PMID:21507918; http://dx.doi.org/10.1093/cid/cir185
   PubMed Web of Science ®Google Scholar
• Mikulska M, Furfaro E, Del Bono V, Raiola AM, Ratto S, Bacigalupo A, Viscoli C. Piperacillin/tazobactam (Tazocin) seems to be no longer responsible for false-positive results of the galactomannan assay. J Antimicrob Chemother 2012; 67:1746-8; PMID:22499998; http://dx.doi.org/10.1093/jac/dks111
   PubMed Web of Science ®Google Scholar
• Vergidis P, Razonable RR, Wheat LJ, Estes L, Caliendo AM, Baden LR, Wingard JR, Baddley J, Assi M, Norris S, et al. Reduction in false-positive Aspergillus serum galactomannan enzyme immunoassay results associated with use of piperacillin-tazobactam in the United States. J Clin Microbiol 2014; 52:2199-201; PMID:24719434; http://dx.doi.org/10.1128/JCM.00285-14
   PubMed Web of Science ®Google Scholar
• Cruciani M, Mengoli C, Loeffler J, Donnelly P, Barnes R, Jones BL, Klingspor L, Morton O, Maertens J. Polymerase chain reaction blood tests for the diagnosis of invasive aspergillosis in immunocompromised people. Cochrane Database Syst Rev 2015; CD009551; PMID:26424726; http://dx.doi.org/10.1002/14651858.CD009551.pub3
   Web of Science ®Google Scholar
• Avni T, Levy I, Sprecher H, Yahav D, Leibovici L, Paul M. Diagnostic accuracy of PCR alone compared to galactomannan in bronchoalveolar lavage fluid for diagnosis of invasive pulmonary aspergillosis: a systematic review. J Clin Microbiol 2012; 50:3652-8; PMID:22952268; http://dx.doi.org/10.1128/JCM.00942-12
   PubMed Web of Science ®Google Scholar
• Maertens J, Theunissen K, Verhoef G, Verschakelen J, Lagrou K, Verbeken E, Wilmer A, Verhaegen J, Boogaerts M, Van Eldere J. Galactomannan and CT-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis 2005; 41:1242-50; PMID:16206097; http://dx.doi.org/10.1086/496927
   PubMed Web of Science ®Google Scholar
• Hebart H, Klingspor L, Klingebiel T, Loeffler J, Tollemar J, Ljungman P, Wandt H, Schaefer-Eckart K, Dornbusch HJ, Meisner C, et al. A prospective randomized controlled trial comparing PCR-based and empirical treatment with liposomal amphotericin B in patients after allo-SCT. Bone Marrow Transplant 2009; 43:553-61; PMID:19079316; http://dx.doi.org/10.1038/bmt.2008.355
   PubMed Web of Science ®Google Scholar
• Cordonnier C, Pautas C, Maury S, Vekhoff A, Farhat H, Suarez F, Dhedin N, Isnard F, Ades L, Kuhnowski F, et al. Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial. Clin Infect Dis 2009; 48:1042-51; PMID:19281327; http://dx.doi.org/10.1086/597395
   PubMed Web of Science ®Google Scholar
• Morrissey CO, Chen SC, Sorrell TC, Milliken S, Bardy PG, Bradstock KF, Szer J, Halliday CL, Gilroy NM, Moore J, et al. Galactomannan and PCR versus culture and histology for directing use of antifungal treatment for invasive aspergillosis in high-risk haematology patients: a randomised controlled trial. Lancet Infect Dis 2013; 13:519-28; PMID:23639612; http://dx.doi.org/10.1016/S1473-3099(13)70076-8
   PubMed Web of Science ®Google Scholar
• Duarte RF, Sanchez-Ortega I, Cuesta I, Arnan M, Patino B, Fernandez de Sevilla A, Gudiol C, Ayats J, Cuenca-Estrella M. Serum galactomannan-based early detection of invasive aspergillosis in hematology patients receiving effective antimold prophylaxis. Clin Infect Dis 2014; 59:1696-702; PMID:25165088; http://dx.doi.org/10.1093/cid/ciu673
   PubMed Web of Science ®Google Scholar
• Stanzani M, Sassi C, Battista G, Cavo M, Lewis RE. Improved radiographic imaging of invasive fungal disease: the cornerstone to antifungal stewardship in the hematology units? Curr Fungal Infect Rep 2016; 10:78-86; http://dx.doi.org/10.1007/s12281-016-0258-1
   Web of Science ®Google Scholar
• Stanzani M, Lewis RE, Fiacchini M, Ricci P, Tumietto F, Viale P, Ambretti S, Baccarani M, Cavo M, Vianelli N. A risk prediction score for invasive mold disease in patients with hematological malignancies. PLoS One 2013; 8:e75531; PMID:24086555; http://dx.doi.org/10.1371/journal.pone.0075531
   PubMed Web of Science ®Google Scholar
• Dodds-Ashley E. Management of drug and food interactions with azole antifungal agents in transplant recipients. Pharmacotherapy 2010; 30:842-54; PMID:20653361; http://dx.doi.org/10.1592/phco.30.8.842
   PubMed Web of Science ®Google Scholar
• Bruggemann RJ, Alffenaar JW, Blijlevens NM, Billaud EM, Kosterink JG, Verweij PE, Burger DM. Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis 2009; 48:1441-58; PMID:19361301; http://dx.doi.org/10.1086/598327
   PubMed Web of Science ®Google Scholar
• Lempers VJ, Martial LC, Schreuder MF, Blijlevens NM, Burger DM, Aarnoutse RE, Bruggemann RJ. Drug-interactions of azole antifungals with selected immunosuppressants in transplant patients: strategies for optimal management in clinical practice. Curr Opin Pharmacol 2015; 24:38-44; PMID:26218924; http://dx.doi.org/10.1016/j.coph.2015.07.002
   PubMed Web of Science ®Google Scholar
• Lempers VJ, Bruggemann RJ. Antifungal therapy: drug-drug interactions at your fingertips. J Antimicrob Chemother 2016; 71:285-9; PMID:26553846; http://dx.doi.org/10.1093/jac/dkv350
   PubMed Web of Science ®Google Scholar
• Soler-Palacin P, Frick MA, Martin-Nalda A, Lanaspa M, Pou L, Rosello E, de Heredia CD, Figueras C. Voriconazole drug monitoring in the management of invasive fungal infection in immunocompromised children: a prospective study. J Antimicrob Chemother 2012; 67:700-6; PMID:22190607; http://dx.doi.org/10.1093/jac/dkr517
   PubMed Web of Science ®Google Scholar
• Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008; 46:201-11; PMID:18171251; http://dx.doi.org/10.1086/524669
   PubMed Web of Science ®Google Scholar
• Park WB, Kim NH, Kim KH, Lee SH, Nam WS, Yoon SH, Song KH, Choe PG, Kim NJ, Jang IJ, et al. The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial. Clin Infect Dis 2012; 55:1080-7; PMID:22761409; http://dx.doi.org/10.1093/cid/cis599
   PubMed Web of Science ®Google Scholar
• Trifilio S, Ortiz R, Pennick G, Verma A, Pi J, Stosor V, Zembower T, Mehta J. Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2005; 35:509-13; PMID:15654347; http://dx.doi.org/10.1038/sj.bmt.1704828
   PubMed Web of Science ®Google Scholar
• Lebeaux D, Lanternier F, Elie C, Suarez F, Buzyn A, Viard JP, Bougnoux ME, Lecuit M, Jullien V, Lortholary O. Therapeutic drug monitoring of posaconazole: a monocentric study with 54 adults. Antimicrob Agents Chemother 2009; 53:5224-9; PMID:19752284; http://dx.doi.org/10.1128/AAC.00939-09
   PubMed Web of Science ®Google Scholar
• Jang SH, Colangelo PM, Gobburu JV. Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma. Clin Pharmacol Ther 2010; 88:115-9; PMID:20505665; http://dx.doi.org/10.1038/clpt.2010.64
   PubMed Web of Science ®Google Scholar
• Bryant AM, Slain D, Cumpston A, Craig M. A post-marketing evaluation of posaconazole plasma concentrations in neutropenic patients with haematological malignancy receiving posaconazole prophylaxis. Int J Antimicrob Agents 2011; 37:266-9; PMID:21236645; http://dx.doi.org/10.1016/j.ijantimicag.2010.11.021
   PubMed Web of Science ®Google Scholar
• Shields RK, Clancy CJ, Vadnerkar A, Kwak EJ, Silveira FP, Massih RC, Pilewski JM, Crespo M, Toyoda Y, Bhama JK, et al. Posaconazole serum concentrations among cardiothoracic transplant recipients: factors impacting trough levels and correlation with clinical response to therapy. Antimicrob Agents Chemother 2011; 55:1308-11; PMID:21189337; http://dx.doi.org/10.1128/AAC.01325-10
   PubMed Web of Science ®Google Scholar
• Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ, Helfgott D, Holowiecki J, Stockelberg D, Goh YT, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007; 356:348-59; PMID:17251531; http://dx.doi.org/10.1056/NEJMoa061094
   PubMed Web of Science ®Google Scholar
• Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, Tarantolo SR, Greinix H, Morais de Azevedo W, Reddy V, Boparai N, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007; 356:335-47; PMID:17251530; http://dx.doi.org/10.1056/NEJMoa061098
   PubMed Web of Science ®Google Scholar
• Ananda-Rajah MR, Grigg A, Slavin MA. Making sense of posaconazole therapeutic drug monitoring: a practical approach. Curr Opin Infect Dis 2012; 25:605-11; PMID:23086185; http://dx.doi.org/10.1097/QCO.0b013e328359a56e
   PubMed Web of Science ®Google Scholar
• Dolton MJ, Ray JE, Marriott D, McLachlan AJ. Posaconazole exposure-response relationship: evaluating the utility of therapeutic drug monitoring. Antimicrob Agents Chemother 2012; 56:2806-13; PMID:22391534; http://dx.doi.org/10.1128/AAC.05900-11
   PubMed Web of Science ®Google Scholar
• Campoli P, Al Abdallah Q, Robitaille R, Solis NV, Fielhaber JA, Kristof AS, Laverdiere M, Filler SG, Sheppard DC. Concentration of antifungal agents within host cell membranes: a new paradigm governing the efficacy of prophylaxis. Antimicrob Agents Chemother 2011; 55:5732-9; PMID:21930891; http://dx.doi.org/10.1128/AAC.00637-11
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Raad I, Patterson TF, Chandrasekar P, Donowitz GR, Graybill R, Greene RE, Hachem R, Hadley S, Herbrecht R, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007; 44:2-12; PMID:17143808; http://dx.doi.org/10.1086/508774
   PubMed Web of Science ®Google Scholar
• Jung DS, Tverdek FP, Kontoyiannis DP. Switching from posaconazole suspension to tablets increases serum drug levels in leukemia patients without clinically relevant hepatotoxicity. Antimicrob Agents Chemother 2014; 58:6993-5; PMID:25199774; http://dx.doi.org/10.1128/AAC.04035-14
   PubMed Web of Science ®Google Scholar
• de With K, Steib-Bauert M, Knoth H, Dorje F, Strehl E, Rothe U, Maier L, Kern WV. Hospital use of systemic antifungal drugs. BMC Clin Pharmacol 2005; 5:1; PMID:15703083; http://dx.doi.org/10.1186/1472-6904-5-1
   PubMedGoogle Scholar
• Newland JG, Stach LM, De Lurgio SA, Hedican E, Yu D, Herigon JC, Prasad PA, Jackson MA, Myers AL, Zaoutis TE. Impact of a prospective-audit-with-feedback antimicrobial stewardship program at a children's hospital. J Pediatric Infect Dis Soc 2012; 1:179-86; PMID:26619405; http://dx.doi.org/10.1093/jpids/pis054
   PubMedGoogle Scholar
• Seo SK, Lo K, Abbo LM. Current state of antimicrobial stewardship at solid organ and hematopoietic cell transplant centers in the United States. Infect Control Hosp Epidemiol 2016; 1-6. [ Epub ahead of print]; PMID:27457099; http://dx.doi.org/10.1017/ice.2016.149
   PubMed Web of Science ®Google Scholar
• Mondain V, Lieutier F, Hasseine L, Gari-Toussaint M, Poiree M, Lions C, Pulcini C. A 6-year antifungal stewardship programme in a teaching hospital. Infection 2013; 41:621-8; PMID:23463185; http://dx.doi.org/10.1007/s15010-013-0431-1
   PubMed Web of Science ®Google Scholar
• Micallef C, Aliyu SH, Santos R, Brown NM, Rosembert D, Enoch DA. Introduction of an antifungal stewardship programme targeting high-cost antifungals at a tertiary hospital in Cambridge, England. J Antimicrob Chemother 2015; 70:1908-11; PMID:25722302; http://dx.doi.org/10.1093/jac/dkv040
   PubMed Web of Science ®Google Scholar
• Lopez-Medrano F, San Juan R, Lizasoain M, Catalan M, Ferrari JM, Chaves F, Lumbreras C, Montejo JC, Herreros de Tejada A, Aguado JM. A non-compulsory stewardship programme for the management of antifungals in a university-affiliated hospital. Clin Microbiol Infect 2013; 19:56-61; PMID:22551077; http://dx.doi.org/10.1111/j.1469-0691.2012.03891.x
   PubMed Web of Science ®Google Scholar
• Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, Reboli AC, Schuster MG, Vazquez JA, Walsh TJ, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis 2016; 62:e1-50; PMID:26679628; http://dx.doi.org/10.1093/cid/civ1194
   PubMed Web of Science ®Google Scholar
• Bal AM, Shankland GS, Scott G, Imtiaz T, Macaulay R, McGill M. Antifungal step-down therapy based on hospital intravenous to oral switch policy and susceptibility testing in adult patients with candidaemia: a single centre experience. Int J Clin Pract 2014; 68:20-7; PMID:24341299; http://dx.doi.org/10.1111/ijcp.12231
   PubMed Web of Science ®Google Scholar
• Shah DN, Yau R, Weston J, Lasco TM, Salazar M, Palmer HR, Garey KW. Evaluation of antifungal therapy in patients with candidaemia based on susceptibility testing results: implications for antimicrobial stewardship programmes. J Antimicrob Chemother 2011; 66:2146-51; PMID:21700622; http://dx.doi.org/10.1093/jac/dkr244
   PubMed Web of Science ®Google Scholar